O tratamento Têm a possibilidade de ser feito com aplicador em linha e/ou caneta depende da condição da pele e do formato do rosto do paciente.
Injection in the back of the hand may result in temporary difficulty performing activities. RADIESSE® may cause nodules, bumps or lumps in the back of the hand and can last up to 1 year.
Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment sitio following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.
Tell your health care provider if you have any diseases, injuries or disabilities of the hand, if you have a history forming large, raised scars or if you have had any other skin treatments such as skin peels.
Check out these common questions for more info about Radiesse Injectables and what your patients can expect from treatment.
Calcium hydroxylapatite, or CaHA, is what makes Radiesse unique as a dermal filler treatment. Radiesse is composed of CaHA suspended in an aqueous gel copyright.3
CaHA particles form a “scaffold” that stimulates fibroblasts to produce collagen for up to a year and elastin for up to nine months (after only one injection).5-10
Healthcare practitioners should fully familiarize themselves with the product, the product educational materials and the entire package insert.
RADIESSE® (+) is contraindicated in patients with known hypersensitivity to lidocaine or anesthetics of the amide type.
The safety and effectiveness for use in the lips has not been established. There have been published reports of nodules associated with the use of these products injected into the lips.
These products contain calcium hydroxylapatite (CaHA) particles sculptra that are radiopaque and are clearly visible on CT Scans and may be visible in standard, plain radiography.
RADIESSE® is also used for correcting volume loss in the back of the hands. RADIESSE® (+) is also used for improving moderate to severe loss of jawline contour in adults over 21 years old.
The FDA now requires that specific training on the newly-approved jawline indication for fillers be made available by the manufacturer to providers.
Delayed-onset inflammation near the sitio of injection is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.